# Grace Therapeutics (GRCE) — Earnings

GRCE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/grce/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q1 2026 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.21 |
| EPS estimate | −$0.22 |
| EPS surprise | +4.55% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q1 2026 | Aug 12, 2025 | −$0.22 | −$0.21 | 4.55% | — | — |
| Q4 2025 | Jun 23, 2025 | −$0.28 | $0.11 | 139.64% | — | — |
| Q3 2025 | Feb 13, 2025 | −$0.34 | −$0.36 | -7.46% | — | — |
| Q2 2025 | Nov 13, 2024 | −$0.37 | −$0.30 | 18.92% | — | — |
| Q1 2025 | Aug 9, 2024 | −$0.27 | −$0.24 | 9.43% | — | — |
| Q4 2024 | Jun 21, 2024 | −$0.35 | −$0.17 | 51.43% | — | — |
| Q3 2024 | Feb 12, 2024 | −$0.23 | −$0.21 | 8.70% | — | — |
| Q2 2024 | Nov 13, 2023 | −$0.26 | −$0.43 | -65.38% | — | — |
| Q1 2024 | Aug 11, 2023 | −$0.28 | −$0.54 | -92.86% | — | — |
| Q4 2023 | Jun 23, 2023 | −$0.84 | −$3.90 | -364.29% | — | — |
| Q3 2023 | Feb 14, 2023 | −$0.74 | −$0.54 | 27.03% | — | — |
| Q2 2023 | Nov 14, 2022 | $0.00 | −$0.66 | 0.00% | — | — |
| Q1 2023 | Aug 11, 2022 | $0.00 | −$0.60 | 0.00% | — | — |
| Q4 2022 | Jun 21, 2022 | −$0.78 | −$0.54 | 30.77% | — | — |
| Q3 2022 | Feb 14, 2022 | −$0.48 | −$0.54 | -12.50% | — | — |
| Q2 2022 | Nov 10, 2021 | $0.00 | −$0.18 | 0.00% | — | — |
| Q1 2022 | Aug 12, 2021 | $0.00 | −$0.48 | 0.00% | — | — |
| Q4 2021 | Jun 22, 2021 | −$1.92 | −$1.44 | 25.00% | — | — |
| Q3 2021 | Feb 9, 2021 | −$1.92 | −$1.44 | 25.00% | — | $81,000.00 |
| Q2 2021 | Nov 16, 2020 | −$2.65 | −$2.88 | -8.81% | — | — |

## Frequently Asked Questions

### When did Grace Therapeutics (GRCE) last report earnings?

Grace Therapeutics last reported on Aug 12, 2025, covering fiscal Q1 2026.

### Did GRCE beat earnings estimates?

Yes. Grace Therapeutics reported EPS of −$0.21 for Q1 2026 against a −$0.22 estimate — a 4.55% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).